This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tuesday's Small-Cap Winners & Losers

Telik (TELK) suffered a 71% freefall after the California-based biotech announced two disappointing late-stage clinical studies of its experimental cancer drug Telcyta. The trials, which compared the drug to existing therapies in advanced nonsmall-cell lung cancer and ovarian cancer, both failed to meet their primary endpoints of statistically significant improvement in overall survival. Shares were plunging $11.48 to $4.78.

Tecumseh Products (TECUA) jumped on an upgrade by a Robert W. Baird analyst to neutral from underperform. Shares of the Michigan-based compressor-products maker were up $1.99, or 12%, to $18.54.

EpiCept (EPCT) gained after the Tarrytown, N.Y.-based pharmaceutical company said it will license the rights to its back-pain treatment, a transdermal patch containing bupivacaine, for up to $1.9 million to Durect (DRRX). The licensee, a drugmaker based in Cupertino, Calif., will pay Epicept $1 million up front and an additional $9 million in milestone payments, plus royalties on future sales. EpiCept shares were up 13 cents, or 9.4%, to $1.52. Durect shares were slipping 4 cents, or 0.9%, to $4.45.

Adventrx Pharmaceuticals (ANX) shares swelled on news that the Food and Drug Administration had approved clinical testing of its proposed cancer drug ANX-530, deeming it to be bioequivalent to Navelbine, an existing cancer treatment approved for use in nonsmall-cell lung cancer. The San Diego company expects patient recruitment for the initial study to begin in January. Shares were gaining 13 cents, or 4.9%, to $2.77.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ANX $0.73 0.00%
TELK $2.75 -8.33%
TECUA $6.11 1.66%
AAPL $95.03 -2.90%
FB $116.73 7.20%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs